1. Home
  2. QNC vs KMDA Comparison

QNC vs KMDA Comparison

Compare QNC & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QNC

Quantum eMotion Corp. Common Shares

N/A

Current Price

$2.64

Market Cap

434.7M

Sector

N/A

ML Signal

N/A

Logo Kamada Ltd.

KMDA

Kamada Ltd.

HOLD

Current Price

$8.23

Market Cap

488.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNC
KMDA
Founded
2007
1990
Country
Canada
Israel
Employees
5
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
434.7M
488.6M
IPO Year
2026
2013

Fundamental Metrics

Financial Performance
Metric
QNC
KMDA
Price
$2.64
$8.23
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$14.00
AVG Volume (30 Days)
524.5K
55.5K
Earning Date
04-28-2026
05-13-2026
Dividend Yield
N/A
2.96%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$13.94
Revenue Next Year
N/A
$9.84
P/E Ratio
N/A
$24.59
Revenue Growth
N/A
N/A
52 Week Low
$1.90
$6.35
52 Week High
$3.41
$9.35

Technical Indicators

Market Signals
Indicator
QNC
KMDA
Relative Strength Index (RSI) 50.07 42.53
Support Level $2.03 $7.96
Resistance Level N/A $8.40
Average True Range (ATR) 0.24 0.19
MACD 0.08 0.01
Stochastic Oscillator 72.38 41.25

Price Performance

Historical Comparison
QNC
KMDA

About QNC Quantum eMotion Corp. Common Shares

Quantum eMotion Inc is dedicated to developing of a new generation of quantum-safe encryption for the quantum computing age. It is a developer of a new generation of cryptographic solutions under the acquisition of licenses. It allows clients and partners to develop secure quantum-safe encryption that can protect anything from consumer and enterprise devices like mobile phones, computers, the Internet of Things, and networking equipment to demanding cloud-based applications, servers, and military devices.

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Share on Social Networks: